Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Phase of Trial: Phase III
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs Gilteritinib (Primary) ; Cytarabine; Cytarabine; Etoposide; Fludarabine; Granulocyte colony-stimulating factors; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms COMMODORE
- Sponsors Astellas Pharma
- 30 Oct 2017 Status changed from not yet recruiting to recruiting.
- 12 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
- 12 Jun 2017 New trial record